Nephrology Times最新文献_第5页

AKI Risk Factors Up, but Incidence Down in AMI Patients AMI患者AKI危险因素上升，但发病率下降

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414765.89291.D3

M. Coleman

引用次数: 0

Stem Cell Induction Successful in Small Trial of Living-Related Kidney Transplants 干细胞诱导在活体肾移植的小型试验中成功

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414763.04540.27

M. Hogan

引用次数: 0

Peginesatide Approval Introduces Competition into Antianemia Drug Market pegineside的批准为抗贫血药物市场带来了竞争

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414759.81668.40

M. Hogan

{"title":"Peginesatide Approval Introduces Competition into Antianemia Drug Market","authors":"M. Hogan","doi":"10.1097/01.NEP.0000414759.81668.40","DOIUrl":"https://doi.org/10.1097/01.NEP.0000414759.81668.40","url":null,"abstract":"There’s a new player in anemia management for patients on dialysis— once-monthly peginesatide, which was approved by the Food and Drug Administration (FDA) on March 27. “In the United States where only epoetin alfa, as Epogen, and darbepoetin are available in the dialysis market, this represents a novel agent to compete with the existing agents in the marketplace,” said Nephrology Times Editorial Board Chair Ajay K. Singh, MBBS, MBA, in a phone interview. “It’s a major milestone.” Dr. Singh is Director of Global Programs and Associate Professor of Medicine at Harvard Medical School, as well as a physician in the Division of Renal Medicine and Director of Postgraduate Medical Education in the Department of Medicine at Brigham and Women’s Hospital. Peginesatide is given less frequently than epoetin alfa, which typically is administered one to three times a week. “The advantage is clearly the oncemonthly administration, putting a lot of convenience to the management of anemia,” said Brigitte Schiller, MD, Chief Medical Offi cer of Satellite Healthcare and a member of the Scientifi c Advisory Board of Affymax, which discovered peginesatide and is co-commercializing it in the United States with Takeda, under the brand name Omontys. “I would think of it as a simplifying anemia management approach for the nurses, the providers, and for patients,” Dr. Schiller said in a phone interview. Peginesatide Approval Introduces Competition into Antianemia Drug Market","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115782815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treating Glomerulonephritis: Follow Transplantʼs Steroid-Limiting Lead 治疗肾小球肾炎:遵循移植的类固醇限制铅

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414761.66421.2B

A. Salama

引用次数: 0

Integrated Nephrology Care Model Gains Traction 综合肾脏病护理模式获得牵引力

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414760.58797.73

M. Hogan

引用次数: 0

Dilutional Hyponatremia in Cirrhosis: Updating the Standard of Care 肝硬化稀释性低钠血症:更新护理标准

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414766.96915.6B

M. Atta

引用次数: 0

Health Information Exchange Addresses CROWNWeb Submission Gaps 健康信息交换地址CROWNWeb提交差距

Nephrology Times Pub Date : 2012-04-01 DOI: 10.1097/01.NEP.0000414764.12163.99

M. Coleman

引用次数: 0

In Central Americaʼs Kidney Disease Epidemic, Risk Varies with Altitude 在中美洲的肾脏疾病流行，风险随海拔而变化

Nephrology Times Pub Date : 2012-03-01 DOI: 10.1097/01.NEP.0000413836.42434.43

M. Coleman

引用次数: 1

Anti-HIV Drug Independently Predicts Kidney Risk 抗艾滋病药物独立预测肾脏风险

Nephrology Times Pub Date : 2012-03-01 DOI: 10.1097/01.NEP.0000413835.42434.98

B. Roehr

引用次数: 0

In a Surprising Finding, Paricalcitol Fails to Improve Cardiac Measures 一项令人惊讶的发现，帕立西醇不能改善心脏状况

Nephrology Times Pub Date : 2012-03-01 DOI: 10.1097/01.NEP.0000413832.96692.2A

F. Lowry

{"title":"In a Surprising Finding, Paricalcitol Fails to Improve Cardiac Measures","authors":"F. Lowry","doi":"10.1097/01.NEP.0000413832.96692.2A","DOIUrl":"https://doi.org/10.1097/01.NEP.0000413832.96692.2A","url":null,"abstract":"The active vitamin D compound paricalcitol had no effect on left ventricular mass index (LVMI) or measures of diastolic dysfunction in patients with chronic kidney disease (CKD), according to the results of a multinational, double-blind, randomized, placebo-controlled trial. The fi ndings, from the Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial, were published in the Journal of the American Medical Association (JAMA 2012;307:674-684). The negative result surprised the PRIMO investigators. “Animal studies suggested paricalcitol would have a dramatic effect and improve cardiovascular health, but that did not translate to the human studies,” said lead author Ravi Thadhani, MD, MPH, Associate Professor of Medicine at Harvard Medical School, in an interview. “In the human studies, we found that there were fewer hospitalizations for cardiovascularrelated disease and lower levels of BNP [brain natriuretic peptide], which is a marker of cardiac stress, but we didn’t fi nd changes in the cardiac mass, and this was surprising,” Dr. Thadhani said. “This suggests that, if indeed this type of agent has a dramatic effect on the heart, it’s not because it reduces cardiac mass; it works through other mechanisms that may play a role in heart failure.” Paricalcitol is used to treat elevated parathyroid hormone levels in patients with CKD who are vitamin D defi cient. Data have suggested that the compound may also decrease cardiovascularrelated morbidity and mortality, In a Surprising Finding, Paricalcitol Fails to Improve Cardiac Measures","PeriodicalId":380758,"journal":{"name":"Nephrology Times","volume":"341 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132168533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0